Has bimetinib/bemetinib been included in medical insurance?

Binimetinib has not yet been officially launched in mainland China and is therefore not included in the national medical insurance directory. As an internationally recognized innovative targeted anti-cancer drug, it has been approved for marketing in the United States, Europe, Japan and other countries. It is mainly used to treat patients with unresectable or metastatic melanoma and non-small cell lung cancer (NSCLC) carrying BRAF V600E or V600K mutations, and is often used in combination with the BRAF inhibitor Encorafenib. Since there is no formal approval in China, the drug cannot be purchased through medical insurance channels. If patients need to use it, they usually need to obtain it through overseas medical institutions or cross-border pharmacies.

In the international market, the price of bimetinib is relatively high. Taking the United States as an example, its 50mg capsules are commonly packaged in 180 capsules/box, and the price of a single box can range from several thousand dollars. The specific cost depends on the dosage plan and the patient's course of treatment. If combined with encofenib, the overall cost of treatment will be higher. However, some countries and regions have included the drug in commercial insurance or specific cancer relief projects to reduce the financial burden on patients.

Although it has not yet been launched in China, the clinical application and efficacy data of bimetinib globally are relatively mature. Overseas studies have shown that compared with BRAF inhibitors alone, the treatment regimen combined with bimetinib can significantly extend the progression-free survival (PFS) of patients, reduce the incidence of drug resistance, and improve overall survival (OS) data. Due to these clinical advantages, regulatory agencies in many countries have included it in priority review or rare disease treatment drug lists, laying the foundation for subsequent promotion and use in more countries.

In general, bimetinib has not yet been included in China's medical insurance system, but as a leading international targeted therapy drug, it has a high degree of recognition in the global anti-cancer field. With the acceleration of the drug review and approval system and the growing demand for precision cancer treatment, the possibility of the drug being launched in China and being approved for medical insurance is gradually increasing in the future, bringing new treatment hope to patients with BRAF mutant melanoma and lung cancer.

Reference materials:https://go.drugbank.com/drugs/DB11967